Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7Z6Z6
UPID:
PLPL5_HUMAN
Alternative names:
GS2-like protein
Alternative UPACC:
Q7Z6Z6; B1AHL8; B3KPR1; Q6ZST0
Background:
Patatin-like phospholipase domain-containing protein 5, also known as GS2-like protein, is characterized by its significant triacylglycerol lipase activity. This enzyme plays a crucial role in lipid metabolism, breaking down triacylglycerols into fatty acids and glycerol, essential processes for energy production and lipid homeostasis in cells.
Therapeutic significance:
Understanding the role of Patatin-like phospholipase domain-containing protein 5 could open doors to potential therapeutic strategies. Its pivotal function in lipid metabolism suggests its involvement in metabolic disorders, offering a promising target for drug discovery aimed at treating lipid-related diseases.